Literature DB >> 26328479

Lipoprotein(a) and livedoid vasculopathy: A new thrombophilic factor?

P R Criado1, D P S Espinell2, P Barreto2, T H B Di Giacomo2, M N Sotto3.   

Abstract

Livedoid vasculopathy is a chronic disorder characterised by recurrent reticulated purpura on lower extremities, associated with painful purpuric or necrotic macules and ulcerations. Current knowledge indicates LV to be a thrombo-occlusive vasculopathy of cutaneous blood vessels; exact pathogenesis is yet to be understood. Elevated levels of lipoprotein(a) have been found in LV patients. To date, elevated plasma levels of lipoprotein(a) are considered an independent and causal genetic risk factor for the development of cardiovascular disease, as well as a relevant factor in hypercoagulable states. Because of its structural homology with plasminogen, Lp(a) might have important anti-fibrinolytic properties. Altered endothelial function and participation in immune and autoimmune processes, such as antiphospholipid syndrome, are also potential mechanisms of Lp(a) involvement in LV pathogenesis. Lp(a) is part of the wound healing process; the possibility of Lp(a) serum elevation to reflect an acute-phase reagent in LV scenario is also considered. The objective of this review is to examine the possible association of lipoprotein(a) with LV pathogenesis, based on its effects on thrombogenesis, fibrinolysis and autoimmunity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26328479     DOI: 10.1016/j.mehy.2015.08.009

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

1.  Dermoscopic features of livedoid vasculopathy.

Authors:  Stephen Chu-Sung Hu; Gwo-Shing Chen; Chi-Ling Lin; Yang-Chun Cheng; Yung-Song Lin
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 2.  Skin manifestations of COVID-19: A worldwide review.

Authors:  See Wei Tan; Yew Chong Tam; Choon Chiat Oh
Journal:  JAAD Int       Date:  2020-12-16

3.  Adalimumab in Treating Refractory Livedoid Vasculopathy.

Authors:  Xiao-Wen Huang; Huan-Xin Zheng; Meng-Lei Wang; Wan-Mei He; Mei-Xin Feng; Kang Zeng; Li Li
Journal:  Vaccines (Basel)       Date:  2022-04-01

4.  Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Authors:  Maria Rosa Burg; Carolin Mitschang; Tobias Goerge; Stefan Werner Schneider
Journal:  Front Med (Lausanne)       Date:  2022-10-03

5.  Is macular lymphocytic arteritis limited to the skin? Long-term follow-up of seven patients.

Authors:  Thâmara Cristiane Alves Batista Morita; Gabriela Franco Sturzeneker Trés; Paulo Ricardo Criado
Journal:  An Bras Dermatol       Date:  2019-11-22       Impact factor: 1.896

Review 6.  Lessons from dermatology about inflammatory responses in Covid-19.

Authors:  Paulo Ricardo Criado; Carla Pagliari; Francisca Regina Oliveira Carneiro; Juarez Antonio Simões Quaresma
Journal:  Rev Med Virol       Date:  2020-07-12       Impact factor: 11.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.